Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement

Memorial Sloan Kettering Cancer Center (MSK)

Status: Completed

Conditions: Histiocytic Disorders; Erdheim-Chester Disease; Langerhans Cell Histiocytosis

Treatments: Procedure: biopsy; Radiation: F-choline PET Scan; Device: FDG-PET

Study type: Observational

Funder types: Other

Identifiers

NCT02608619

15-268

Details and patient eligibility

About

The main purpose of this study is to discover how 18F-cholineFCH distributes in the body, and see if it can distinguish active histiocytes (tumor) from inflammatory (non- tumor) cells. This tracer has the potential to give the investigators' team more information when trying to identify the tumor cells that are most important to collect with biopsy. In addition, the study will measure levels of 18F-cholineFCH in the biopsy tissue.

Enrollment: 3 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years old
• Suspected but pathologically unconfirmed diagnosis of Erdheim-Chester disease or Langerhans cell histiocytosis or other histiocytic disorder on the basis of clinical diagnosis, radiologic features, or findings from prior biopsies

Or

• Confirmed diagnosis of Erdheim-Chester disease or Langerhans cell histiocytosis or other histiocytic disorder and requiring additional diagnostic imaging and biopsy to determine mutational status in order to determine therapeutic options.

Exclusion criteria

• Inability to undergo or cooperate with PET/CT scan (e.g., claustrophobia)
• Pregnant or nursing female

Trial design

3 participants in 1 patient group

PET Imaging

Description:

This study will enroll patients who have a clinical diagnosis of a systemic histiocytic disorder, and who are scheduled to undergo confirmatory biopsies of the systemic lesions, that were identified by standard imaging modalities.

Treatment:

Radiation: F-choline PET Scan

Device: FDG-PET

Procedure: biopsy